InvestSMART

Antisense Therapeutics Limited (ASX: ANP) - Announcements

Current share price for ANP : $0.058 0.003 (4.92%)+

ASX company news and announcements for Antisense Therapeutics Limited (ANP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Antisense Therapeutics Limited (ANP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Antisense Therapeutics Limited (ANP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Antisense Therapeutics Limited (ANP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 Annual General Meeting Presentation 15 Dec 2021 10:21AM $0.185 $0.058 fallen by 68.65%
$52 Positive UK PIP Decision & PDCO opinion ratification by EMA 14 Dec 2021 9:25AM $0.185 $0.058 fallen by 68.65%
$52 ATL1102 Toxicology Protocol submitted to US FDA 9 Dec 2021 9:48AM $0.180 $0.058 fallen by 67.78%
$52 Entitlement Offer Closing Date Extended 23 Nov 2021 4:25PM $0.205 $0.058 fallen by 71.71%
$52 Update - Proposed issue of securities - ANP 23 Nov 2021 4:18PM $0.205 $0.058 fallen by 71.71%
$52 Notice of Annual General Meeting/Proxy Form 15 Nov 2021 9:15AM $0.210 $0.058 fallen by 72.38%
$52 Change of Director's Interest Notice - CG 11 Nov 2021 3:27PM $0.210 $0.058 fallen by 72.38%
$52 Becoming a substantial holder 8 Nov 2021 4:00PM $0.215 $0.058 fallen by 73.02%
$52 Prospectus 5 Nov 2021 9:42AM $0.240 $0.058 fallen by 75.83%
$52 Application for quotation of securities - ANP 5 Nov 2021 9:36AM $0.240 $0.058 fallen by 75.83%
$52 Placement and Cleansing Notice 5 Nov 2021 9:35AM $0.240 $0.058 fallen by 75.83%
$52 Investor Presentation 1 Nov 2021 11:51AM $0.295 $0.058 fallen by 80.34%
$52 Proposed issue of securities - ANP 1 Nov 2021 11:49AM $0.295 $0.058 fallen by 80.34%
$52 Positive PDCO opinion and A$20m Placement 1 Nov 2021 11:49AM $0.295 $0.058 fallen by 80.34%
$52 2021 Annual Report 29 Oct 2021 9:54AM $0.295 $0.058 fallen by 80.34%
$52 Appendix 4G and Corporate Governance Statement 29 Oct 2021 9:20AM $0.295 $0.058 fallen by 80.34%
$52 Quarterly Report and Appendix 4C 29 Oct 2021 9:00AM $0.295 $0.058 fallen by 80.34%
$52 Trading Halt 28 Oct 2021 9:47AM $0.295 $0.058 fallen by 80.34%
$52 Initial Director's Interest Notice 8 Oct 2021 9:19AM $0.220 $0.058 fallen by 73.64%
$52 Antisense Therapeutics appoints new Non-Executive Director 4 Oct 2021 9:17AM $0.195 $0.058 fallen by 70.26%
$52 Positive feedback received on Paediatric Investigation Plan 30 Sep 2021 9:47AM $0.198 $0.058 fallen by 70.63%
$52 New data supports ATL1102s broader clinical potential 24 Sep 2021 9:29AM $0.200 $0.058 fallen by 71%
$52 ANP to present new proteomics data at WMS Congress 2021 20 Sep 2021 9:37AM $0.175 $0.058 fallen by 66.86%
$52 Appendix 4E and Full Year Statutory Accounts 25 Aug 2021 5:42PM $0.170 $0.058 fallen by 65.88%
$52 ANP to participate in development of DMD Guidance for FDA 24 Aug 2021 8:31AM $0.170 $0.058 fallen by 65.88%

126 - 150 of 707 results

Page 6 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.